Brief: Sanofi Makes Milestone Payment To Innate Pharma After Start of SAR'514/IPH6401 Clinical Trial

Innate Pharma SA

11/07/2023 06:17

July 11 (Reuters) - Innate Pharma SA  IPH.PA :
    * FIRST PATIENT DOSED IN SAR’514 / IPH6401 PHASE 1/2
CLINICAL
TRIAL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    * INNATE PHARMA AND PARTNER SANOFI ADVANCES SAR'514 /
IPH6401, A
TRIFUNCTIONAL ANTI-BCMA NKP46XCD16 NK CELL ENGAGER FROM A JOINT
RESEARCH COLLABORATION 
    * START OF TRIAL HAS TRIGGERED A MILESTONE PAYMENT FROM
SANOFI TO
INNATE

Source text for Eikon:  ID:nBwLQXgDa 
Further company coverage:  IPH.PA ;  SASY.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))